Schwartz C J, Kimberg D V, Sheerin H E, Field M, Said S I
J Clin Invest. 1974 Sep;54(3):536-44. doi: 10.1172/JCI107790.
Vasoactive intestinal peptide (VIP), originally isolated from hog small intestinal mucosa, has been shown to cause small intestinal secretion. More recently, this peptide has been identified in the plasma and tumors of patients with the so-called "pancreatic cholera" syndrome. In order to explore the possible role of VIP in the pathogenesis of this syndrome, we examined the effects of this peptide and other hormones on the cyclic AMP levels, adenylate cyclase activity, and ion transport in in vitro preparations of ileal mucosa. In rabbit ileal mucosa, VIP (20 mug/ml) caused a prompt fivefold increase in cyclic AMP level, whereas nine other hormones, which have been postulated to cause intestinal secretion, failed to exert such an effect. Pentagastrin and glucagon also failed to increase cyclic AMP levels in canine ileal mucosa. An increase in mucosal cyclic AMP levels was observed at a VIP concentration of 0.1 mug/ml and appeared to be nearly maximal at 2.0 mug/ml. VIP (100 mug/ml) stimulated adenylate cyclase activity in a membrane preparation from rabbit ileal mucosa. Secretin (6.0 x 10(-5) M) failed to do so. When added to the serosal side of isolated rabbit ileal mucosa clamped in an Ussing chamber, VIP (2 mug/ml) increased short-circuit current (SCC) and caused net secretion of both Cl and Na. Net Cl secretion exceeded net Na secretion. These effects of VIP on mucosal cyclic AMP metabolism and ion transport are similar to those observed with cholera enterotoxin and certain prostaglandins. VIP was also tested with normal human ileal mucosa. At a concentration of 2 mug/ml it caused a fivefold increase in cyclic AMP level and an increase in SCC of the same magnitude as that caused by 5 mM theophylline. Addition of a second 2-mug/ml dose of VIP and addition of theophylline after VIP produced no further change in SCC. We conclude the VIP stimulates adenylate cyclase and active ion secretion in both rabbit and human ileal mucosa. This may be related to the pathogenesis of diarrhea in patients with the pancreatic cholera syndrome.
血管活性肠肽(VIP)最初是从猪小肠黏膜中分离出来的,已被证明可引起小肠分泌。最近,在患有所谓“胰性霍乱”综合征的患者的血浆和肿瘤中发现了这种肽。为了探讨VIP在该综合征发病机制中的可能作用,我们研究了这种肽和其他激素对回肠黏膜体外制剂中环磷酸腺苷(cAMP)水平、腺苷酸环化酶活性和离子转运的影响。在兔回肠黏膜中,VIP(20微克/毫升)可使cAMP水平迅速升高五倍,而其他九种据推测可引起肠道分泌的激素则未能产生这种作用。五肽胃泌素和胰高血糖素也未能增加犬回肠黏膜中的cAMP水平。在VIP浓度为0.1微克/毫升时可观察到黏膜cAMP水平升高,在2.0微克/毫升时似乎接近最大值。VIP(100微克/毫升)刺激了兔回肠黏膜膜制剂中的腺苷酸环化酶活性。促胰液素(6.0×10⁻⁵摩尔/升)则未能做到这一点。当添加到置于尤斯灌流小室中的离体兔回肠黏膜的浆膜侧时,VIP(2微克/毫升)增加了短路电流(SCC),并导致氯离子(Cl)和钠离子(Na)的净分泌。Cl的净分泌超过了Na的净分泌。VIP对黏膜cAMP代谢和离子转运的这些作用与霍乱肠毒素和某些前列腺素所观察到的作用相似。还用正常人回肠黏膜对VIP进行了测试。在浓度为2微克/毫升时,它使cAMP水平升高五倍,使SCC增加的幅度与5毫摩尔/升茶碱所引起的相同。在VIP后添加第二剂2微克/毫升的VIP以及添加茶碱均未使SCC进一步改变。我们得出结论,VIP刺激兔和人回肠黏膜中的腺苷酸环化酶和活性离子分泌。这可能与胰性霍乱综合征患者腹泻的发病机制有关。